SciSparc Secures U.S. Patent for Innovative Cannabinoid Antimicrobial Technology
NeuroThera Labs, a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), has been granted a significant U.S. patent covering a novel cannabinoid-enhanced platform designed to combat antimicrobial resistance, particularly against challenging pathogens like Methicillin-resistant Staphylococcus aureus (MRSA). The United States Patent and Trademark Office issued the patent, which protects a groundbreaking combination of established antibiotics and cannabinoids that could potentially restore effectiveness against resistant bacterial strains.
Patent Landscape and Technological Innovation
The newly granted patent represents a strategic expansion of NeuroThera's intellectual property portfolio, joining previously secured patents in the U.S. and Europe. The technology combines well-established antibiotics with cannabinoids including Δ9-Tetrahydrocannabinol (THC), Cannabidiol (CBD), and N-acylethanolamines like palmitoylethanolamide (PEA).
Preclinical studies have demonstrated the platform's potential to enhance antimicrobial activity, potentially addressing a critical challenge in healthcare: the growing threat of antibiotic-resistant infections. The approach leverages existing antibiotics' extensive safety data while introducing a novel mechanism to improve their efficacy against resistant pathogens.
Scientific Context and Global Health Implications
The patent arrives at a critical moment in global healthcare. According to The Lancet, MRSA directly caused approximately 130,000 deaths worldwide in 2021—more than double the 57,000 deaths in 2019. The World Health Organization reports that bacterial antimicrobial resistance (AMR) directly caused 1.14 million deaths in 2021, with a global median methicillin resistance rate of 27.1% in Staphylococcus aureus bloodstream infections.
Competitive and Market Dynamics
The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by escalating antimicrobial resistance challenges. NeuroThera's approach addresses a significant market need: developing innovative solutions that can enhance existing antibiotics' efficacy while improving safety profiles.
The "antimicrobial-sparing" effect demonstrated in preclinical studies could potentially eliminate the constant need for new antibiotics, helping mitigate serious side effects associated with resistance development.